Johnson & Johnson (NYSE:JNJ) today announced results from an open-label, multicenter Phase 1 study evaluating an investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in ...

National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50; Many respondents report undergoing ...

Johnson & Johnson (JNJ) stock is in focus as the company's Erda-iDRS drug delivery system hits the main goal in a Phase 1 ...

A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

A new report examines whether Iowa farmers, highly exposed to pesticides, are getting cancer more often than others in the ...

IBRX stock surges nearly 300% YTD as Anktiva sales jump and global approvals expand, while premium valuation and single-drug ...

The study also demonstrated complete and durable responses in patients with recurrent intermediate-risk disease, along with ...

ImmunityBio IBRX has entered a new phase as a commercial-stage immunotherapy developer. The company’s near-term trajectory is ...

Rising case numbers attributed to older population, with overall underlying risk remaining flat or decreasing over the last 30 years, report finds ...

CEO Richard Adcock said physicians could prescribe Anktiva for papillary bladder cancer if it is added to NCCN treatment guidelines. ・The company recently filed a supplemental biologics license ...

According to the latest research study published by Vyansa Intelligence, the Cardiovascular Devices Market in the United States is projected to grow at a CAGR of around 9.35% during 2026-2032. The ...

From street crime to national security threats, criminal activity is increasingly being enabled by digital, globalized, and sophisticated crime networks. To keep Canadians safe, Canada's new ...